金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived, Glu19-Val624, with a C-terminal 10-His tag Accession #:NP_082342 N-terminal Sequence Analysis:Glu19 Structure:Disulfide-linked homodimer Purity:>90%, by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin Level: Predicted Molecular Mass:69 kDa SDS-PAGE:74 kDa, reducing conditions Activity:Measured by its ability to cleave the fluorogenic peptide substrate, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin (Boc-IEGR-AMC). The specific activity is >100 pmol/min/µg, as measured under the described conditions. Formulation:Supplied as a 0.2 µm filtered solution in HEPES and NaCl.See Certificate of Analysis for details. Molecule Information: Coagulation Factor XI Entrez Gene IDs: 2160 (Human); 109821 (Mouse) Background: Coagulation Factor XI Coagulation Factor XI is synthesized in the liver and circulates in the plasma as a disulfide bond-linked dimer complexed with High Molecular Weight Kininogen. Factor XI is converted into active XIa either via the contact phase of blood coagulation or through Thrombin-mediated activation on the platelet surface. The resulting XIa converts Coagulation Factor IX into IXa, which subsequently activates Coagulation Factor X (Xa). Xa then can mediate Coagulation Factor II/Thrombin activation. Patients with factor XI deficiency are prone to excessive bleeding after hemostatic challenge.